24/7 Market News Snapshot 20 May, 2025 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

May 20, 2025

DENVER, Colo., 20 May, 2025 (www.247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp. (KTTA) is experiencing a notable surge in pre-market trading, currently priced at $0.951, reflecting a 0.97% increase from the prior close of $0.942. This upward trend is supported by robust trading activity, with a volume of 5.54 million shares indicating strong investor interest and potential for further momentum. Technical analysis suggests that a breakout beyond existing resistance could lead to additional gains, while key support levels and broader market sentiments will significantly impact short-term price movements. Overall, KTTA’s recent performance signals a positive outlook in the biotech sector, driven by rising investor engagement.

In a significant development, Pasithea Therapeutics has also published promising preclinical research on PAS-004, a next-generation macrocyclic MEK inhibitor designed to address immune-mediated inflammatory diseases, notably inflammatory bowel disease (IBD) and ankylosing spondylitis. Collaborating with a prestigious research institute, the company reported that PAS-004 outperformed the FDA-approved MEK inhibitor selumetinib in inhibiting the ETS2 pathway, a key factor in chronic inflammation.

During the study, PAS-004 consistently demonstrated superior efficacy in downregulating ETS2 target genes and related MEK1/2 pathway genes, integral to managing inflammatory responses. Notable findings include significant suppression of ETS2-regulated genes at all tested doses and a marked reduction in macrophage functions such as cytokine production and reactive oxygen species generation. These results suggest a promising approach to mitigating inflammation.

Dr. Tiago Reis Marques, CEO of Pasithea, expressed optimism regarding PAS-004’s potential as a transformative oral treatment for inflammatory diseases, particularly IBD, supported by favorable safety data from earlier clinical trials. Dr. Larry Steinman, Executive Chairman, emphasized that these findings may lead to breakthroughs in therapeutic strategies for chronic inflammatory disorders, demonstrating Pasithea’s continued commitment to addressing critical patient needs in this domain.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.